Cell Therapy Technologies Market

The global cell therapy technologies market is anticipated to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4%. Major growth drivers of the market are the increased funding and investment in cell therapy and the growing size of the cell and gene therapy pipeline.

The market for cell therapy technologies is consolidated. Prominent players in the cell therapy technologies market are Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc.  (US), Avantor, Inc. (US), Bio-Techne (US), and Fresenius SE & Co KGAA (Germany), BD (US), and among others.

To know about the assumptions considered for the study download the pdf brochure

In June 2024, Danaher Corporation launched an HIV panel to advance virology research, representing innovation in its NGS portfolio. In July 2024, Thermo Fisher Scientific launched a novel pre-transplant risk assessment assay to assess the risk of kidney transplant rejection.

Danaher Corporation is among the leading companies in cell therapy technologies. The company has evolved as one of the greatest companies in the biotechnology market due to its acquisition of Pall Corporation for USD 13.8 billion in August 2015 and the Biopharma business (Cytiva) of GE Healthcare for USD 21 billion in March 2020. The company is aggressive toward strategic alliances, mergers, and new product development. For instance, in April 2024, Cytiva introduced new cell lines under the ELEVECTA brand to better address growing demand in viral vector manufacturing.

Merck KGaA is also one of the leading companies in the cell therapy technologies market. The company operates in the cell therapy technologies market through its life science business segment. Its competitive edge stems from a broad product portfolio, a wide geographic reach, and the active use of both organic and inorganic growth strategies. A notable development was the acquisition of Mirus Bio (US) in August 2024, which strengthened Merck’s integrated offering for viral vector production.

Thermo Fisher Scientific Inc. is a leaders in cell therapy technologies. The company offers an extensive range of instruments, consumables, and services. The company benefits from its global footprint, diversified product mix, and continuous investment in new solutions. For instance, in June 2024, Thermo Fisher launched the Thermo Scientific Heracell VIOS 250i AxD CO2 incubators, featuring tailored support for emerging automated cell therapy manufacturing processes.

Market Ranking

The cell therapy technologies market is highly competitive, with a few global players together accounting for a substantial share of industry revenues. Thermo Fisher Scientific maintains a strong position with its broad portfolio of cell processing equipment, culture systems, reagents, analytics, and digital solutions, backed by extensive service and logistics capabilities that support customers from early research through commercial CGT manufacturing. Danaher Corporation, through Cytiva and Pall, is another key participant, offering integrated platforms for cell processing, single-use bioprocessing, viral vector manufacturing, and automation that enable seamless scale-up from bench to cGMP. Merck KGaA and other major suppliers contribute meaningfully, leveraging strengths in media, sera and reagents, viral vector and gene delivery technologies, and high-performance analytics tailored for advanced therapies. The remaining market is fragmented among regional equipment manufacturers, component providers, and niche CGT technology specialists focusing on areas such as closed, modular manufacturing, single-cell analytics, and AI-enabled process monitoring. Recent trends indicate strong momentum driven by advances in automation, integrated platforms, and digitalization, along with ongoing efforts to reduce the cost of goods and improve scalability across autologous and allogeneic cell therapy production.

Related Reports:

Cell Therapy Technologies Market by Product (Media, Sera, Reagents, Vessels, Equipment), Process (Expansion, Isolation, Characterization, Collection, Preservation, Distribution, QC), Type (T-cells, Stem Cells), Application (Cancer) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com